Trials / Recruiting
RecruitingNCT07222267
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- Sponsor
- BeOne Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BG-75202 | Administered orally. |
| DRUG | CDK4 Inhibitor | Administered orally. |
| DRUG | Estrogen Receptor Antagonist | Administered by intramuscular injection. |
| DRUG | Aromatase Inhibitor | Administered orally. |
Timeline
- Start date
- 2025-12-11
- Primary completion
- 2029-09-30
- Completion
- 2037-01-13
- First posted
- 2025-10-29
- Last updated
- 2026-04-15
Locations
20 sites across 5 countries: United States, Australia, China, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07222267. Inclusion in this directory is not an endorsement.